TrialThe Lancet. Oncology2024
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
Kanwal Raghav et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
104 papers cite itlatest 60 shown
this paperpooled ittrialcites it